Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 7/7/2020
SIETES contiene 93061 citas

 
 
<< anterior 21 a 40 de 979 siguiente >>
Presentar resultados
Seleccionar todas
21.Enlace a cita originalTiene citas relacionadas
Rodríguez F, Harrington RA. Cholesterol, cardiovascular risk, statins, PCSK9 inhibitors, and the future of LDL-C lowering. JAMA 2016;316:1967-8. [Ref.ID 100983]
23. Cita con resumen
Leibowitz M, Karpati T, Cohen-Stavi CJ, Feldman BS, Hoshen M, Bitterman H, Suissa S, Balicer RD. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic heart disease taking statin treatment. JAMA Intern Med 2016;176:1105-13. [Ref.ID 100700]
24. Cita con resumen
Anónimo. Alirocumab. Prescrire 2016;36:331-2. [Ref.ID 100534]
25. Cita con resumen
Anónimo. Évolocumab. Prescrire 2016;36:326-31. [Ref.ID 100533]
26.Enlace a cita original
Warren JB, Dimmitt SB, Stampfer HG. Cholesterol trials and mortality. Br J Clin Pharmacol 2016;82:168-77. [Ref.ID 100478]
27.Tiene citas relacionadas Cita con resumen
Ravnskov U, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, Hynes N, Kendrick M, Langsjoen PH, Malhotra A, Mascitelli L, McCully KS, Ogushi Y, Okuyama H, Rosch PJ, Schersten T, Sultan S, Sundberg R. Lack of an association or an inverse association between low-density lipoprotein cholesterol and mortality in the elderly: a systematic review. BMJ Open 2016:28 de junio. [Ref.ID 100445]
28.Tiene citas relacionadas Cita con resumen
Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, Xavier D, Avezum A, Leiter LA, Piegas LS, Parkhomenko A, Keltai M, Keltai K, Silwa K, Chazova I, Peters RJG, Held C, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Accini JL, McKelvie R, Pogue J, Jung H, Liu L, Díaz R, Dans A, Dagenais G, for the HOPE-3 Investigators. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med 2016;374:2032-43. [Ref.ID 100363]
29.Tiene citas relacionadas Cita con resumen
Yusuf S, Bosch J, Dagenais G, Xavier D, Pais P, López-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Peters RJG, Held C, Chazova I, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Sánchez-Vallejo G, McKelvie R, Pogue J, Jung H, Gao P, Díaz R, Lonn E, for the HOPE-3 Investigators. Cholesterol lowering in intermediate. Risk persons without cardiovascular disease. N Engl J Med 2016;374:2021-31. [Ref.ID 100362]
30.Tiene citas relacionadas Cita con resumen
Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Pals P, Díaz R, Xavier D, Sliwa K, Dans A, Avezum A, Piegas LS, Keltai K, Keltai M, Chazova I, Peters RJG, Held C, Yusoff K, Lewis BS, Jansky P, Parkhomenko A, Khunti K, Toff WD, Reid CM, Varigos J, Leiter LA, Molina DI, McKelvie R, Pogue J, Wilkinson J, Hung H, Dagenais G, Yusuf S, for the HOPE-3 Investigators. Blood-pressure lowering in intermediate. Risk persons without cardiovascular disease. N Engl J Med 2016;374:2009-20. [Ref.ID 100361]
31.Tiene citas relacionadas Cita con resumen
Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceska R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA, for the GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance. The GAUSS-3 randomized clinical trial. JAMA 2016;315:1580-90. [Ref.ID 100239]
32.Tiene citas relacionadas Cita con resumen
Waters DD, Hsue PY, Bangalore S. PCSK9 inhibitors for statin intolerance?. JAMA 2016;315:1571-2. [Ref.ID 100238]
33. Cita con resumen
Pintó X, García Gómez MC. Nuevos tratamientos para la hipercolesterolemia. Med Clin (Barc) 2016;146:172-7. [Ref.ID 100102]
34. Cita con resumen
Korhonen MJ, Ruokoniemi P, Ilomäki J, Meretoja A, Helin-Salmivaara A, Huupponen R. Adherence to statin therapy and the incidence of ischemic stroke in patients with diabetes. Pharmacoepidemiol Drug Saf 2016;25:161-9. [Ref.ID 100096]
35. Cita con resumen
Anónimo. Two new lipid-regulating drugs. Drug Ther Bull 2016;54:18-21. [Ref.ID 100095]
36. Cita con resumen
Anónimo. Evolocumab (Repatha) - A second PCSK9 inhibitor to lower LDL-cholesterol. The Medical Letter on Drug and Therapeutics Bulletin 2015;57:140-1. [Ref.ID 99812]
37. Cita con resumen
Naci H, Lehman R, Wouters OJ, Goldacre B, Yudkin JS. Rethinking the appraisal and approval of drugs for type 2 diabetes. BMJ 2015;351:h5260. [Ref.ID 99594]
38. Cita con resumen
Anónimo. Eli Lilly ends development of experimental heart drug. DIA Daily 2016:13 de octubre. [Ref.ID 99559]
39. Cita con resumen
Allen K, Pearson-Stuttard J, Hooton W, Diggle P, Capewell S, O’Flaherty M. Potential of trans fats policies to reduce socioeconomic inequalities in mortality from coronary heart disease in England: cost effectiveness modelling study. BMJ 2015;351:h4583. [Ref.ID 99541]
Seleccionar todas
 
<< anterior 21 a 40 de 979 siguiente >>